Redeye provides a research update following the Q2 report recently published by Initiator
Pharma. While the company is still awaiting a licensing deal for pudafensine within the ED
indication, Initiator Pharma has now expanded its clinical pipeline into vulvodynia.
Strengthened by the recent rights issue and the financial backing by MAC Clinical
Research, the planned phase IIa trial marks a strategic move into female-focused
indications with high unmet medical need and commercial potential. Following this, we
make some changes to our valuation model. However, we reiterate our base case valuation
of SEK15
LÄS MER
